These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27254806)

  • 1. Potential for Drug-Drug Interactions with Adjunctive Tramadol Use in Treatment of Obsessive-Compulsive Disorder.
    Brown EE; Davies S
    Can J Psychiatry; 2016 May; 61(5):308-9. PubMed ID: 27254806
    [No Abstract]   [Full Text] [Related]  

  • 2. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder.
    Shapira NA; Keck PE; Goldsmith TD; McConville BJ; Eis M; McElroy SL
    Depress Anxiety; 1997; 6(4):170-3. PubMed ID: 9559288
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid remission of OCD with tramadol hydrochloride.
    Goldsmith TB; Shapira NA; Keck PE
    Am J Psychiatry; 1999 Apr; 156(4):660-1. PubMed ID: 10200754
    [No Abstract]   [Full Text] [Related]  

  • 4. Possible interaction of tramadol and antidepressants.
    Reus VI; Rawitscher L
    Am J Psychiatry; 2000 May; 157(5):839. PubMed ID: 10784494
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors.
    Frost DA; Soric MM; Kaiser R; Neugebauer RE
    Pharmacotherapy; 2019 Jun; 39(6):724-729. PubMed ID: 31038218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar effects of tramadol and venlafaxine in major depressive disorder.
    Reeves RR; Cox SK
    South Med J; 2008 Feb; 101(2):193-5. PubMed ID: 18364623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mania and tramadol-fluoxetine combination.
    Gonzalez-Pinto A; Imaz H; De Heredia JL; Gutierrez M; Micó JA
    Am J Psychiatry; 2001 Jun; 158(6):964-5. PubMed ID: 11384912
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors.
    Nelson EM; Philbrick AM
    Ann Pharmacother; 2012 Dec; 46(12):1712-6. PubMed ID: 23212934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Drug Ther Bull; 1995 Jun; 33(6):47-8. PubMed ID: 7587998
    [No Abstract]   [Full Text] [Related]  

  • 12. Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder.
    Harris E; Eng HY; Kowatch R; Delgado SV; Saldaña SN
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):347-53. PubMed ID: 20807074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
    Andrade C
    J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
    [No Abstract]   [Full Text] [Related]  

  • 14. Pain management discussion forum: serious interaction among frequently used drugs for chronic pain.
    Breivik H
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):170-1. PubMed ID: 24801976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia and obsessive-compulsive disorder.
    Devulapalli K; Nasrallah HA
    Am J Psychiatry; 2010 Nov; 167(11):1407-8. PubMed ID: 21041254
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence.
    Hammerness PG; Vivas FM; Geller DA
    J Pediatr; 2006 Feb; 148(2):158-65. PubMed ID: 16492422
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
    Vythilingum B; Cartwright C; Hollander E
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and potential pharmacological treatments for obsessive-compulsive disorder.
    Davidson J; Bjorgvinsson T
    Expert Opin Investig Drugs; 2003 Jun; 12(6):993-1001. PubMed ID: 12783603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder.
    Corregiari FM; Bernik M; Cordeiro Q; Vallada H
    Clinics (Sao Paulo); 2012; 67(4):335-40. PubMed ID: 22522758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of obsessive-compulsive disorder in an adult].
    Kähkönen S; Holmberg N
    Duodecim; 2010; 126(11):1310-6. PubMed ID: 20681354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.